Sensus Healthcare reported second quarter 2026 revenues of $2.3 million, a decrease of $5.0 million or 68.5% from the prior year period's $7.3 million. The decline was driven by selling only 11 units compared to 19 in Q2 2025, with revenue recognition for eight additional units delayed until Q3 due to financing approval timing. Net loss widened significantly to $8.7 million, or $0.53 per share, from a net loss of $1.0 million, or $0.06 per share, in the same period last year. Adjusted EBITDA deteriorated to negative $3.0 million from negative $1.8 million. The company reported cash and equivalents of $15.2 million as of June 30, 2026. Sensus Healthcare operates in the medical device industry, developing non-invasive superficial radiotherapy treatments for skin conditions.